X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
budget impact analysis (3) 3
cost-benefit analysis - methods (3) 3
health care sciences & services (3) 3
health policy (3) 3
health policy & services (3) 3
humans (3) 3
public health, environmental and occupational health (3) 3
biomedical technology - economics (2) 2
budgets (2) 2
clinical trials as topic (2) 2
cost-effectiveness (2) 2
economic evaluation (2) 2
economics (2) 2
evidence-based medicine (2) 2
guidance (2) 2
guidelines (2) 2
health care costs (2) 2
internal medicine (2) 2
methodology (2) 2
modeling (2) 2
policy making (2) 2
advisory committees (1) 1
biomedical technology (1) 1
breast-cancer (1) 1
budget (1) 1
budgets - methods (1) 1
budgets - standards (1) 1
care (1) 1
clinical study (1) 1
cost benefit analysis (1) 1
cost calculator (1) 1
cost control (1) 1
cost of treatment (1) 1
cost-benefit analysis - standards (1) 1
decision making, organizational (1) 1
development and progression (1) 1
dosage and administration (1) 1
drug therapy (1) 1
economic evaluations (1) 1
economic-evaluation (1) 1
europe (1) 1
fees, pharmaceutical (1) 1
financial analysis (1) 1
financial audit (1) 1
guidelines as topic (1) 1
health policy - economics (1) 1
hepatitis c (1) 1
index medicus (1) 1
inhibitors (1) 1
insurance, health, reimbursement - economics (1) 1
lanreotide autogel (1) 1
model (1) 1
models, economic (1) 1
natalizumab (1) 1
neuroendocrine tumors (1) 1
oncology (1) 1
original paper (1) 1
patient outcomes (1) 1
peginterferon alfa-2a (1) 1
peginterferon alfa-2b (1) 1
poland (1) 1
ribavirin (1) 1
statistics as topic (1) 1
thrombolysis (1) 1
uncertainty (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Expert Review of Pharmacoeconomics & Outcomes Research, ISSN 1473-7167, 10/2004, Volume 4, Issue 5, p. 495
Pegylated interferon-[[alpha].sub.2a]] (Pegasys[R], Roche) and pegylated interferon-[[alpha].sub.2b] (Peg-Intron[R], Schering-Plough) with ribavirin... 
Peginterferon alfa-2b | Peginterferon alfa-2a | Patient outcomes | Development and progression | Dosage and administration | Hepatitis C | Drug therapy | Cost benefit analysis | Ribavirin
Journal Article
Wspólczesna Onkologia, ISSN 1428-2526, 09/2013, Volume 17, Issue 5, p. 460
  Aim of the study: To assess resource utilization and costs of treatment with lanreotide AUTOGEL 120 mg (ATG120) administered as part of routine acromegaly... 
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.